Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 15;11(6):e0157324.
doi: 10.1371/journal.pone.0157324. eCollection 2016.

Putting PrEP into Practice: Lessons Learned from Early-Adopting U.S. Providers' Firsthand Experiences Providing HIV Pre-Exposure Prophylaxis and Associated Care

Affiliations

Putting PrEP into Practice: Lessons Learned from Early-Adopting U.S. Providers' Firsthand Experiences Providing HIV Pre-Exposure Prophylaxis and Associated Care

Sarah K Calabrese et al. PLoS One. .

Abstract

Optimizing access to HIV pre-exposure prophylaxis (PrEP), an evidence-based HIV prevention resource, requires expanding healthcare providers' adoption of PrEP into clinical practice. This qualitative study explored PrEP providers' firsthand experiences relative to six commonly-cited barriers to prescription-financial coverage, implementation logistics, eligibility determination, adherence concerns, side effects, and anticipated behavior change (risk compensation)-as well as their recommendations for training PrEP-inexperienced providers. U.S.-based PrEP providers were recruited via direct outreach and referral from colleagues and other participants (2014-2015). One-on-one interviews were conducted in person or by phone, transcribed, and analyzed. The sample (n = 18) primarily practiced in the Northeastern (67%) or Southern (22%) U.S. Nearly all (94%) were medical doctors (MDs), most of whom self-identified as infectious disease specialists. Prior experience prescribing PrEP ranged from 2 to 325 patients. Overall, providers reported favorable experiences with PrEP implementation and indicated that commonly anticipated problems were minimal or manageable. PrEP was covered via insurance or other programs for most patients; however, pre-authorization requirements, laboratory/service provision costs, and high deductibles sometimes presented challenges. Various models of PrEP care and coordination with other providers were utilized, with several providers highlighting the value of clinical staff support. Eligibility was determined through joint decision-making with patients; CDC guidelines were commonly referenced but not considered absolute. Patient adherence was variable, with particularly strong adherence noted among patients who had actively sought PrEP (self-referred). Providers observed minimal adverse effects or increases in risk behavior. However, they identified several barriers with respect to accessing and engaging PrEP candidates. Providers offered a wide range of suggestions regarding content, strategy, and logistics surrounding PrEP training, highlighting sexual history-taking and sexual minority competence as areas to prioritize. These insights from early-adopting PrEP providers may facilitate adoption of PrEP into clinical practice by PrEP-inexperienced providers, thereby improving access for individuals at risk for HIV.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: KHM has conducted research with unrestricted project support from Gilead Sciences and Merck. DSK has conducted research with unrestricted project support from Gilead Sciences. No project support from these sources was applied to the current project. KHM is a senior member of the faculty and advisory board of the National LGBT Health Education Center and an associate editor of and contributor to educational materials provided through the organization’s website, which is a resource to which readers are referred in the discussion. DSK and SKC have contributed to these educational materials as well. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Similar articles

Cited by

References

    1. U.S. Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnosis of HIV Infection in the United States and Dependent Areas, 2014. 2015;26. Available: www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-re....
    1. Mayer KH, Ramjee G. The current status of the use of oral medication to prevent HIV transmission. Current opinion in HIV and AIDS. 2015;10(4):226–32. 10.1097/COH.0000000000000170 - DOI - PMC - PubMed
    1. U.S. Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States– 2014: A clinical practice guideline. 2014. Available: www.cdc.gov/hiv/pdf/prepguidelines2014.pdf.
    1. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: Updated to 2020. 2015. Available: www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf
    1. Grant RM, Koester KA. What people want from sex and preexposure prophylaxis. Current opinion in HIV and AIDS. 2016; 11(1):3–9. 10.1097/COH.0000000000000216 - DOI - PMC - PubMed

MeSH terms

Substances